Current Strategies for the Treatment of Hepatocellular Carcinoma by Modulating the Tumor Microenvironment via Nano-Delivery Systems: A Review.
hepatocellular carcinoma
nano-delivery systems
nanoparticles
target therapy
tumor microenvironment
Journal
International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847
Informations de publication
Date de publication:
2022
2022
Historique:
received:
25
02
2022
accepted:
13
05
2022
entrez:
27
5
2022
pubmed:
28
5
2022
medline:
31
5
2022
Statut:
epublish
Résumé
Liver cancer remains a global health challenge with a projected incidence of over one million cases by 2025. Hepatocellular carcinoma (HCC) is a common primary liver cancer, accounting for about 90% of all liver cancer cases. The tumor microenvironment (TME) is the internal and external environment for tumor development, which plays an important role in tumorigenesis, immune escape and treatment resistance. Knowing that TME is a unique setting for HCC tumorigenesis, exploration of strategies to modulate TME has attracted increasing attention. Among them, the use of nano-delivery systems to deliver therapeutic agents to regulate TME components has shown great potential. TME-modulating nanoparticles have the advantages of protecting therapeutic agents from degradation, enhancing the ability of targeting HCC and reducing systemic toxicity. In this article, we summarize the TME components associated with HCC, including cancer-associated fibroblasts (CAFs), extracellular matrix (ECM), endothelial cells and immune cells, discuss their impact on the HCC progression, and highlight recent studies on nano-delivery systems that modulate these components. Finally, we also discuss opportunities and challenges in this field.
Identifiants
pubmed: 35619893
doi: 10.2147/IJN.S363456
pii: 363456
pmc: PMC9128750
doi:
Substances chimiques
Nanoparticle Drug Delivery System
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2335-2352Informations de copyright
© 2022 Huang et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Int J Mol Sci. 2016 Mar 01;17(3):320
pubmed: 26938527
Hepatology. 2011 Apr;53(4):1192-205
pubmed: 21442631
Acta Pharm Sin B. 2021 Jun;11(6):1365-1378
pubmed: 34221857
Proc Natl Acad Sci U S A. 2017 Jul 11;114(28):E5655-E5663
pubmed: 28652358
Cancer Lett. 2016 Dec 1;383(1):18-27
pubmed: 27693460
Clin Cancer Res. 2012 Jun 15;18(12):3229-41
pubmed: 22669131
Nanomedicine. 2018 Feb 17;14(4):1111-1122
pubmed: 29458212
Nat Med. 2010 Sep;16(9):1009-17
pubmed: 20818376
Cancer Res. 2013 Apr 15;73(8):2412-7
pubmed: 23423979
Immunol Today. 1999 Dec;20(12):561-7
pubmed: 10562707
Am J Pathol. 2000 Apr;156(4):1363-80
pubmed: 10751361
J Control Release. 2011 Aug 10;153(3):198-205
pubmed: 21663778
Nature. 1998 Mar 19;392(6673):245-52
pubmed: 9521319
Annu Rev Immunol. 2003;21:685-711
pubmed: 12615891
J Exp Med. 1998 Jul 20;188(2):341-50
pubmed: 9670046
J Clin Invest. 2016 Oct 3;126(10):3672-3679
pubmed: 27482883
N Engl J Med. 2019 Jul 4;381(1):e2
pubmed: 31269386
Bioact Mater. 2020 Sep 01;6(2):326-332
pubmed: 32954051
Expert Rev Anticancer Ther. 2009 Apr;9(4):503-9
pubmed: 19374603
Cancer Res. 2014 Apr 1;74(7):1890-4
pubmed: 24638984
Int J Nanomedicine. 2021 Feb 25;16:1553-1564
pubmed: 33658783
J Immunother Cancer. 2018 Nov 20;6(1):125
pubmed: 30458889
Hepatology. 2010 Feb;51(2):523-34
pubmed: 19821534
Carbohydr Polym. 2020 Dec 1;249:116887
pubmed: 32933700
Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20009-14
pubmed: 21041659
Oncogenesis. 2019 May 16;8(6):36
pubmed: 31097694
Hepatology. 2006 Oct;44(4):836-43
pubmed: 17006919
Small. 2015 May 20;11(19):2291-304
pubmed: 25641921
PLoS One. 2012;7(7):e40812
pubmed: 22815829
Semin Cell Dev Biol. 2010 Feb;21(1):19-25
pubmed: 19857592
J Am Chem Soc. 2014 Apr 16;136(15):5647-55
pubmed: 24689550
Mol Ther. 2015 Nov;23(11):1772-1782
pubmed: 26278330
J Exp Med. 2002 Aug 19;196(4):417-30
pubmed: 12186835
Pathobiology. 2013;80(3):146-54
pubmed: 23364389
Nat Rev Cancer. 2006 Sep;6(9):674-87
pubmed: 16929323
Cancer Sci. 2019 Jul;110(7):2080-2089
pubmed: 31102428
Nat Rev Cancer. 2006 May;6(5):392-401
pubmed: 16572188
Semin Cancer Biol. 2011 Feb;21(1):35-43
pubmed: 20946957
Clin Cancer Res. 2007 Aug 15;13(16):4677-85
pubmed: 17699845
J Gastroenterol Hepatol. 2000 Apr;15(4):431-6
pubmed: 10824889
Hepatol Int. 2019 Mar;13(2):125-137
pubmed: 30600478
Nat Commun. 2018 Mar 5;9(1):948
pubmed: 29507342
Cell. 2017 Aug 24;170(5):939-955.e24
pubmed: 28803726
Cold Spring Harb Perspect Med. 2012 Mar;2(3):a006536
pubmed: 22393533
Int J Oncol. 2012 Jun;40(6):1733-47
pubmed: 22447316
J Hematol Oncol. 2019 Sep 23;12(1):101
pubmed: 31547836
Biochem Pharmacol. 2003 Oct 1;66(7):1307-17
pubmed: 14505810
Biomaterials. 2015 Oct;67:194-203
pubmed: 26218745
J Exp Clin Cancer Res. 2016 Sep 02;35(1):131
pubmed: 27589954
Mol Pharm. 2018 Aug 6;15(8):3595-3599
pubmed: 29966416
Int J Mol Sci. 2020 Jan 10;21(2):
pubmed: 31936832
Hepatol Int. 2020 Dec;14(6):947-957
pubmed: 33188512
Nat Nanotechnol. 2020 Apr;15(4):313-320
pubmed: 32251383
Curr Opin Gastroenterol. 2007 Nov;23(6):644-6
pubmed: 17906441
J Hepatol. 1999 Aug;31(2):323-31
pubmed: 10453947
Cancer Sci. 2009 Apr;100(4):646-53
pubmed: 19175606
Int J Mol Sci. 2017 Feb 14;18(2):
pubmed: 28216578
Cancer Lett. 2008 Aug 28;267(2):204-15
pubmed: 18448242
Science. 2008 Oct 10;322(5899):271-5
pubmed: 18845758
Cell Immunol. 2009;254(2):149-54
pubmed: 18835598
Hum Gene Ther. 2012 Aug;23(8):837-46
pubmed: 22548488
J Gastroenterol Hepatol. 2002 Aug;17(8):897-907
pubmed: 12164966
Nat Biotechnol. 2007 Oct;25(10):1159-64
pubmed: 17873867
Nanoscale. 2013 Oct 21;5(20):9690-8
pubmed: 23969526
Ann Transl Med. 2020 Aug;8(15):929
pubmed: 32953729
Cell Res. 2009 Feb;19(2):156-72
pubmed: 19153598
Nanomedicine (Lond). 2016 Oct;11(20):2699-2709
pubmed: 27654070
Carcinogenesis. 2015 Aug;36(8):894-903
pubmed: 26026166
J Exp Med. 1997 Mar 3;185(5):817-24
pubmed: 9120387
Cell Biosci. 2020 Oct 31;10(1):127
pubmed: 33292459
Crit Rev Immunol. 2012;32(6):463-88
pubmed: 23428224
Cancer Res. 2013 Aug 1;73(15):4862-71
pubmed: 23907638
Bioorg Med Chem Lett. 2013 Mar 15;23(6):1878-82
pubmed: 23395663
Circ Res. 2005 Nov 25;97(11):1093-107
pubmed: 16306453
Cancer Res. 2017 Feb 1;77(3):719-731
pubmed: 27864344
FEBS Open Bio. 2013 Dec 08;4:43-54
pubmed: 24371721
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Nature. 1998 Feb 19;391(6669):806-11
pubmed: 9486653
PLoS One. 2015 Jul 14;10(7):e0132479
pubmed: 26172046
Bioconjug Chem. 2006 May-Jun;17(3):603-9
pubmed: 16704197
J Immunol. 2000 Sep 1;165(5):2665-70
pubmed: 10946296
Oncotarget. 2018 May 1;9(33):23306-23314
pubmed: 29796190
Adv Mater. 2021 Jun;33(23):e2007603
pubmed: 33945178
J Cancer. 2018 Sep 7;9(18):3278-3286
pubmed: 30271487
J Immunol. 2009 Jul 1;183(1):172-80
pubmed: 19542428
Vaccine. 2012 Jun 22;30(30):4414-8
pubmed: 22546329
Acta Pharm Sin B. 2022 Jan;12(1):339-352
pubmed: 35127390
Science. 2000 Apr 21;288(5465):522-7
pubmed: 10775112
Immunol Rev. 2008 Apr;222:357-68
pubmed: 18364014
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Hepatology. 2015 May;61(5):1591-602
pubmed: 25529917
Curr Opin Genet Dev. 2005 Feb;15(1):102-11
pubmed: 15661540
Br J Cancer. 2008 Nov 4;99(9):1375-9
pubmed: 18797460
Adv Exp Med Biol. 2019;1189:153-177
pubmed: 31758534
Science. 2009 Nov 27;326(5957):1216-9
pubmed: 19965464
World J Gastroenterol. 2005 Nov 7;11(41):6521-4
pubmed: 16425427
Cancer Metastasis Rev. 2020 Sep;39(3):783-803
pubmed: 32601975
J Cell Sci. 2010 Dec 15;123(Pt 24):4195-200
pubmed: 21123617
Mediators Inflamm. 2006;2006(4):78380
pubmed: 17047295
Cell Immunol. 2020 Mar;349:104042
pubmed: 32061376
J Intern Med. 2011 Jan;269(1):64-73
pubmed: 21158979
Oncology. 2017;93 Suppl 1:160-164
pubmed: 29258072
J Cell Mol Med. 2021 Apr;25(7):3511-3523
pubmed: 33713546
Hepatology. 2014 Apr;59(4):1435-47
pubmed: 24242874
Gastroenterology. 2013 Mar;144(3):512-27
pubmed: 23313965
Nanomedicine (Lond). 2020 May 27;:
pubmed: 32458768
J Control Release. 2020 May 10;321:564-575
pubmed: 32112854
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Clin Cancer Res. 2008 Mar 1;14(5):1310-6
pubmed: 18316549
J Biochem Mol Toxicol. 2016 Apr;30(4):186-91
pubmed: 26709120
World J Gastroenterol. 2004 Mar 15;10(6):813-8
pubmed: 15040023
Hepatology. 1992 Jun;15(6):1198-203
pubmed: 1592356
J Biomed Nanotechnol. 2014 Dec;10(12):3576-89
pubmed: 26000371
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
J Biomed Nanotechnol. 2019 May 1;15(5):1018-1032
pubmed: 30890232
J Cell Biol. 2012 Feb 20;196(4):395-406
pubmed: 22351925
EMBO Rep. 2014 Dec;15(12):1243-53
pubmed: 25381661
J Cell Biochem. 2008 Jun 1;104(3):826-39
pubmed: 18189245
Biomaterials. 2016 Aug;98:120-30
pubmed: 27182814
Int J Nanomedicine. 2017 May 09;12:3591-3603
pubmed: 28533682
Cancer Res. 2014 Dec 15;74(24):7168-74
pubmed: 25477332
J Clin Invest. 2008 Apr;118(4):1390-7
pubmed: 18357341
Acta Pharm Sin B. 2018 Jan;8(1):4-13
pubmed: 29872618
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Mar;12(2):e1590
pubmed: 31696664